Zika Virus Infection clinical trials
The registry lists 78 studies for Zika Virus Infection across more than 10 countries. 8 are recruiting or about to start. 53 of them are mainly about Zika Virus Infection (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Zika Virus Infection studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (12) · ModernaTX, Inc. (3) · Institut Pasteur (3) · University of Heidelberg Medical Center (3) · Oswaldo Cruz Foundation (2) · University of Notre Dame (2) · Valneva Austria GmbH (2) · Themis Bioscience GmbH (2)
Who these studies take
Of the 4 Zika Virus Infection studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger. 2 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (50%) | 2 (50%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 3 (75%) | 3 (75%) |
| 85 | 2 (50%) | 2 (50%) |
Across all 78 studies, recruiting or not: 59% stop at 75 or younger and 58% at 65; 47% take children; 9% are for women only and 3% for men only; 63% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Zika Virus Infection studies take
Of 21 phase 1 interventional studies under Zika Virus Infection, half reached primary completion within 15 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 15 mo8–25 · 21 studies | — | — |
| Interventional, no phase | 17 mo7–41 · 14 studies | — | — |
| Observational | 44 mo31–52 · 22 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 78. Browse all 78 → or search them.
- Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsRecruitingNCT013864241 country
- Xpert® Tropical Fever Test on GeneXpert® Edge X SystemEnrolling by invitationNCT075202791 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Neurodevelopmental Outcomes in ZIKV-Exposed ChildrenEnrolling by invitationNCT043989012 countries
- Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne DiseasesNot yet recruitingNCT06859619Not applicable1 country
- Virological and Immunological Determinants of Arbovirus Infection in New CaledoniaRecruitingNCT04619823Not applicable1 country
- Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of WolbachiaRecruitingNCT046153641 country
- Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and MalariaNot yet recruitingNCT046725771 country
- Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in ChildrenCompletedNCT035342451 country
- INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsCompletedNCT03037164Phase 33 countries
- Zika Virus Infection's Neonatal and Pediatric Consequences in French Department of AmericaCompletedNCT028102104 countries
- Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental ModelWithdrawnNCT05589012
- Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian CommunitiesCompletedNCT07517731Not applicable2 countries
- Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At ScaleTerminatedNCT06595745Not applicable1 country
- Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP ChallengeCompletedNCT06805487Phase 11 country
- Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy AdultsCompletedNCT06334393Phase 11 country
- A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)CompletedNCT04514107Not applicable1 country
- A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus AreasCompletedNCT04917861Phase 22 countries
- Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne DiseasesCompletedNCT04343521Not applicable1 country
- Spatial Repellents for Aedes-borne Virus Control in Sri LankaCompletedNCT05452447Not applicable1 country
- Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve AdultsCompletedNCT03611946Phase 11 country
- ZIKA Vaccine in Naive SubjectsCompletedNCT02952833Phase 11 country
- Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)CompletedNCT05123222Phase 11 country
- Impacts of a Physical Therapy Protocol on Motor Function in Children With Congenital Zika SyndromeCompletedNCT06900322Not applicable1 country
- GLS-5700 in Dengue Virus-Naïve AdultsCompletedNCT02809443Phase 12 countries
- Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, NicaraguaCompletedNCT041826851 country
- Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative AdultsCompletedNCT04064905Phase 12 countries
- Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult SubjectsCompletedNCT03014089Phase 11 country
- Population Immunity AgaiNst mosquitO-borne Diseases in VanuatuCompletedNCT05153018Not applicable1 country
- Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal CoatingCompletedNCT06268691Not applicable2 countries
- Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and CambodiaCompletedNCT044348461 country
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.CompletedNCT02963909Phase 11 country
- Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)CompletedNCT03624946Phase 11 country
- VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and AdolescentsCompletedNCT03110770Phase 29 countries
- Adherence to Care for Children With Congenital Zika Virus Infection in Puerto RicoCompletedNCT05041439Not applicable1 country
- Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic AreaCompletedNCT03008122Phase 11 country
- Cohort of Patients Infected by an ArbovirusStatus unknownNCT010998525 countries
- Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in UteroCompletedNCT029433041 country
- Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)CompletedNCT02996890Phase 11 country
- ZIKAlliance Pregnant Women CohortCompletedNCT031887317 countries
- ZIKAlliance Children Cohort (ZIKAllianceCH)CompletedNCT033932867 countries
- Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)CompletedNCT04015648Phase 11 country
- ZIKAlliance Natural History StudyWithdrawnNCT032044091 country
- Zika Case Definition and Surveillance StudyCompletedNCT031582334 countries
- International Cohort Study of Children Born to Women Infected With Zika Virus During PregnancyCompletedNCT041187384 countries
- Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, ColombiaCompletedNCT036317191 country
- Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected PatientsWithdrawnNCT03776695Phase 11 country
- Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.CompletedNCT04440774Phase 11 country
- Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.TerminatedNCT03161444Not applicable2 countries
- Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy ParticipantsCompletedNCT03343626Phase 12 countries